Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

The Food and Drug Administration proposed that oral phenylephrine be removed from store shelves becasue the treatment does ...

Oral cancer can be deadly, but early detection through dental exams and innovative screenings can significantly improve ...

Dogs get arthritis for different reasons than humans, and the pain threatens the nature of our relationship with our pets.

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

The reason? An administration review found oral phenylephrine — a common ingredient in over-the-counter cold medications — ...

FDA said its proposal was not based on safety concerns, so companies can still market oral drugs containing the common ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Weight-loss drugs, particularly newer options like GLP-1 receptor agonists, are revolutionising the treatment of obesity and ...